Stephen H Docter

55323839, Jul 2, 1996

May 19, 1995

8/445059

Stevan W. Djuric - Glenview IL
Stephen H. Docter - Mount Prospect IL
Stella S. Yu - Morton Grove IL

G. D. Searle & Co. - Chicago IL

C07D40506
C07D40310
C07D40110
C07D25704

546196

This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof ##STR1## wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl; R. sup. 1 is alkyl; R. sup. 2 is hydrogen, alkyl; R. sup. 6 is alkyl; n is 1 to 5; p is 0 to 6; x is 0 or 2; and R. sup. 4 and R. sup. 5 are independently hydrogen or alkyl or together with N form a cycloalkylamine. The compounds of Formula I are leukotriene B. sub. 4 antagonists and are useful as anti-inflammatory agents and in treating disease conditions mediated by LTB. sub. 4.

53109511, May 10, 1994

Dec 23, 1992

7/995859

Stevan W. Djuric - Glenview IL
Stephen H. Docter - Mount Prospect IL
Stella S. Yu - Morton Grove IL

G.D. Searle & Co. - Chicago IL

C07D31158

549405

This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof ##STR1## wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl; R. sup. 1 is alkyl; R. sup. 2 is hydrogen, alkyl; R. sup. 6 is alkyl; n is 1 to 5; p is 0 to 6; x is 0 or 2; and R. sup. 4 and R. sup. 5 are independently hydrogen or alkyl or together with N form a cycloalkylamine. The compounds of Formula I are leukotriene B. sub. 4 antagonists and are useful as anti-inflammatory agents and in treating disease conditions mediated by LTB. sub. 4.

51243504, Jun 23, 1992

Jun 28, 1990

7/545430

Stevan W. Djuric - Glenview IL
Stephen H. Docter - Mount Prospect IL
Stella S. Yu - Morton Grove IL

G. D. Searle & Co. - Chicago IL

A61K 3135
C07D31166
C07D31158

514456

This invention relates to compounds of Formula I and the stereoisomers and pharmaceutically acceptable salts thereof ##STR1## wherein R is alkyl, alkenyl, alkynyl, or cycloalkylalkyl; R. sup. 1 is alkyl; R. sup. 2 is hydrogen or alkyl; R. sup. 6 is alkyl; n is 1 to 5; p is 0 to 6; x is 0 or 2; and R. sup. 4 and R. sup. 5 are independently hydrogen or alkyl or together with N form a cycloalkylamine. The compounds of Formula I are leukotriene B. sub. 4 antagonists and are useful as anti-inflammatory agents and in treating disease conditions mediated by LTB. sub. 4.

58522107, Dec 22, 1998

Mar 27, 1997

8/825080

Barbara B. Chen - Glenview IL
Helen Y. Chen - Livingston NJ
Michael Clare - Skokie IL
Stephen H. Docter - Chicago IL
Ish Kumar Khanna - Vernon Hills IL
Francis Jan Koszyk - Prospect Heights IL
James W. Malecha - Libertyville IL
Julie Marion Miyashiro - Skokie IL
Thomas D. Penning - Elmhurst IL
Joseph G. Rico - Ballwin MO
Peter G. Ruminski - Ballwin MO
Mark A. Russell - Gurnee IL
Richard Mathias Weier - Lake Bluff IL
Xiangdong Xu - Gurnee IL
Stella S. Yu - Morton Grove IL
Yi Yu - Skokie IL

G. D. Searle & Co. - Chicago IL

C07C24100
C07C20500
C07D23344
C07D23902

562439

The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the. alpha. sub. v. beta. sub. 3 integrin.

20050131050, Jun 16, 2005

Jan 31, 2005

11/048037

John Talley - St. Louis MO, US
Thomas Penning - Elmhurst IL, US
Paul Collins - Deerfield IL, US
Donald Rogier - St. Louis MO, US
James Malecha - Libertyville IL, US
Julie Miyashiro - Chicago IL, US
Stephen Bertenshaw - Brentwood MO, US
Ish Khanna - Vernon Hills IL, US
Matthew Graneto - St. Louis MO, US
Roland Rogers - Richmond Heights MO, US
Jeffery Carter - Chesterfield MO, US
Stephen Docter - Mt. Prospect IL, US
Stella Yu - Morton Grove IL, US

G.D. Searle & Co. - chicago IL

A61K031/416
A61K031/4152
C07D045/02
C07D231/10

514406000, 548364400, 548371100

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: wherein Ris selected from hydrido, alkyl, haloalkyl, alkoxycaronyl, cyano, cyanoalkyl, carboxyl, aminocaronyl, alkylaminocarbonyl, cycloalklaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, amioncarbonylalkyl, alkoxycarbonylcyanoalkenyl and hydroxyalkyl; wherein Ris selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and wherein Ris selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein Ris optionally substituted at a substitutable position with one or more radicals selected from halo alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino; provided Rand Rare not both hydrido; further provided that Ris not carboxyl or methyl when Ris hydrido and when Ris phenyl; further provided that Ris not triazolyl when Ris methyl; further provided that Ris not arakenyl when Ris carboxyl, aminocarbonyl or ethoxycarbonyl; further provided that Ris not phenyl when Ris methyl and Ris carboxyl; and further provided that Ris not unsubstituted thienyl when Ris trifluoromethyl; or a pharmaceutically-acceptable salt thereof.